Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Robert WesolowskiDaniel G StoverMaryam B LustbergAbigail ShobenMeng ZhaoEwa MrozekRachel M LaymanErin MacraeWenrui DuanJun ZhangNathan HallChadwick L WrightSusan GillespieMichael BergerJeffrey J ChalmersAlahdra CareyPriya BalasubramanianBrandon L MillerPeter AmayaEleni AndreopoulouJoseph SparanoCharles L ShapiroMiguel Angel Villalona-CaleroSusan GeyerAlice ChenMichael R GreverMichael V KnoppBhuvaneswari RamaswamyPublished in: The oncologist (2020)
The BROCADE studies suggest that breast cancer patients with BRCA mutation benefit from addition of veliparib to carboplatin plus paclitaxel. This study demonstrates that a higher dose of veliparib is tolerable and active in combination with carboplatin alone. With growing interest in imaging-based early response assessment, the authors demonstrate that decrease in [18]fluoro-3'-deoxythymidine positron emission tomography (FLT-PET) SUVmax during cycle 1 of therapy is associated with response. Collectively, this study established a safety profile of veliparib and carboplatin in advanced breast cancer while also providing additional data on the potential for FLT-PET imaging modality in monitoring therapy response.
Keyphrases
- positron emission tomography
- pet imaging
- computed tomography
- acute myeloid leukemia
- pet ct
- clinical trial
- stem cells
- phase ii study
- randomized controlled trial
- risk assessment
- squamous cell carcinoma
- high resolution
- mesenchymal stem cells
- radiation therapy
- phase iii
- metastatic breast cancer
- mass spectrometry
- climate change
- artificial intelligence
- electronic health record
- big data
- human health
- cell therapy
- placebo controlled